Advertisement
CLPT vs ICUI
Which Stock Would AI Choose? ClearPoint Neuro (CLPT) vs. ICU Medical (ICUI) Stock Comparison
Key Takeaways
- CLPT (ClearPoint Neuro) is a high-growth, small-cap medical device and cell/gene therapy-enabling company, while ICUI (ICU Medical) is a larger, established infusion and critical care device maker.
- CLPT delivered roughly 18% full-year 2025 revenue growth and guided to double-digit growth across all product lines in 2026, but it remains unprofitable on a GAAP (generally accepted accounting principles) basis.
- ICUI returned to full-year profitability in 2025 after a divestiture, but its reported revenue contracted due to the sale of its IV Solutions business, creating a more complex growth story.
- The two stocks represent opposite ends of the medtech spectrum: CLPT offers faster top-line momentum and higher volatility, while ICUI offers scale, cash flow, and a margin-improvement turnaround.
- Relative performance and market positioning differ sharply, with CLPT driven by neuroscience adoption and ICUI driven by integration synergies and margin recovery.
Introduction
Comparing ClearPoint Neuro and ICU Medical brings together two very different healthcare technology businesses under one lens. CLPT is a specialized, growth-oriented developer of navigation and delivery tools for the brain and spine, while ICUI is a global leader in infusion systems and critical care products. This stock comparison is relevant for investors weighing high-growth, early-stage medical innovation against a larger, more mature device franchise undergoing a profitability turnaround. Because the two companies differ in size, growth profile, and risk characteristics, examining their recent performance side by side helps clarify how each might fit into a diversified portfolio or a momentum-focused trading strategy.
CLPT Overview and Recent Performance
ClearPoint Neuro (CLPT) is a device, cell, and gene therapy-enabling company that provides precise navigation for delivering therapeutics to the brain and spine. Its flagship ClearPoint Navigation System holds FDA (U.S. Food and Drug Administration) clearance, and the company partners with dozens of biopharmaceutical firms on preclinical and clinical programs. Recent market activity has centered on accelerating revenue growth: the company reported full-year 2025 revenue of approximately $37 million, up 18% year over year, with fourth-quarter revenue around $10.4 million. Growth has been supported by stronger demand for neurosurgery disposables and biologics and drug delivery services. A key catalyst in recent months was the acquisition of IRRAS Holdings, which added the IRRAflow intracranial fluid-management product line and broadened the company into neurocritical care. Despite a 61% gross margin, CLPT continues to report an operating loss as it invests in its commercial organization, positioning it as a momentum-driven, higher-risk growth name.
ICUI Overview and Recent Performance
ICU Medical (ICUI) is a global leader in infusion systems, infusion consumables, and high-value critical care products used in hospital, alternate-site, and home-care settings. Its recent performance reflects a deliberate portfolio reshaping rather than organic contraction: in May 2025 the company divested its IV Solutions business, which mechanically reduced reported revenue. For full-year 2025, revenue totaled approximately $2.23 billion, down from $2.38 billion the prior year, while the company swung from a net loss to a small full-year profit. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) has remained substantial, and management guided to 2026 adjusted EBITDA of $400 million to $430 million. The investment narrative has focused on integration synergies from the Smiths Medical acquisition, margin improvement, and new pump clearances, though tariffs, a prior FDA warning letter, and restructuring costs have weighed on near-term profitability and sentiment.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the strategies best suited to current market conditions earn a place in the curated Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, ranging from short-term swing strategies to longer-horizon trend-following systems. The curated selection is designed to surface robots whose recent performance and positioning align with prevailing market dynamics, helping traders identify candidates such as CLPT and ICUI for further analysis. Explore the Trending AI Robots page to review the currently featured bots and their live statistics.
Head-to-Head Comparison
The contrast between these two names is defined by scale, growth, and risk. CLPT is a small-cap growth story with a narrower addressable market tied to neurosurgery and central nervous system drug delivery; its top-line is expanding at a double-digit pace, but it has yet to reach profitability, making it more sensitive to sentiment shifts and dilution risk. ICUI is a larger, more diversified franchise with meaningful cash generation and an established installed base of infusion pumps and consumables; its growth is more modest and currently distorted by the IV Solutions divestiture, but its investment case leans on margin recovery and integration execution rather than raw revenue expansion. Sector exposure also differs: CLPT is concentrated in emerging gene and cell therapy infrastructure, whereas ICUI spans hospital-critical-care consumables with recurring revenue characteristics. On risk factors, CLPT faces binary, partner-driven clinical and regulatory catalysts, while ICUI faces tariffs, regulatory remediation, and restructuring costs. For momentum-oriented traders, CLPT's higher growth rate and smaller float may offer greater relative volatility; for stability-oriented investors, ICUI's scale and improving earnings profile may provide more consistent positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely differentiate its assessment by strategy horizon. For trend-following and momentum-oriented models, CLPT may appear more attractive given its sustained double-digit revenue growth, recent acquisition-driven expansion, and clear multi-year catalysts in neuro cell and gene therapy commercialization—though its unprofitable status and volatility suggest a higher-risk profile. For stability- and mean-reversion-focused models, ICUI may screen more favorably on the strength of its return to profitability, substantial adjusted EBITDA, and a defined margin-improvement roadmap, albeit with slower headline growth. In probabilistic terms, the AI would likely favor CLPT for momentum and growth exposure and ICUI for relative stability and earnings quality, meaning the preferred choice depends heavily on the specific strategy and risk tolerance embedded in each bot.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLPT is a StrongBuy and ICUI is a Buy.
CLPT in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 29, 2026
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where CLPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 47 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (26.184) is slightly higher than the industry average of (2.923). P/E Ratio (-7.839) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ICUI's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ICUI turned positive on September 24, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ICUI's RSI Oscillator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICUI as a result. In 62 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
Following a +4.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 193 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 156 of 206 cases where ICUI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 60 cases where ICUI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
ICUI broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.869) is normal, around the industry mean (4.952). ICUI has a moderately high P/E Ratio (134.033) as compared to the industry average of (36.644). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CLPT | ICUI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 89 | |
PRICE GROWTH RATING 1..100 | 86 | 40 | |
P/E GROWTH RATING 1..100 | 14 | 96 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLPT's Valuation (31) in the null industry is somewhat better than the same rating for ICUI (87) in the Medical Specialties industry. This means that CLPT’s stock grew somewhat faster than ICUI’s over the last 12 months.
CLPT's Profit vs Risk Rating (100) in the null industry is in the same range as ICUI (100) in the Medical Specialties industry. This means that CLPT’s stock grew similarly to ICUI’s over the last 12 months.
ICUI's SMR Rating (89) in the Medical Specialties industry is in the same range as CLPT (100) in the null industry. This means that ICUI’s stock grew similarly to CLPT’s over the last 12 months.
ICUI's Price Growth Rating (40) in the Medical Specialties industry is somewhat better than the same rating for CLPT (86) in the null industry. This means that ICUI’s stock grew somewhat faster than CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (14) in the null industry is significantly better than the same rating for ICUI (96) in the Medical Specialties industry. This means that CLPT’s stock grew significantly faster than ICUI’s over the last 12 months.
| CLPT | ICUI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 69% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Advances ODDS (%) | 3 days ago 80% | 11 days ago 68% |
| Declines ODDS (%) | 9 days ago 87% | 2 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLPT’s FA Score shows that 2 FA rating(s) are green while ICUI’s FA Score has 0 green FA rating(s).
- CLPT’s FA Score: 2 green, 3 red.
- ICUI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLPT’s TA Score shows that 4 TA indicator(s) are bullish while ICUI’s TA Score has 5 bullish TA indicator(s).
- CLPT’s TA Score: 4 bullish, 5 bearish.
- ICUI’s TA Score: 5 bullish, 3 bearish.
Price Growth
CLPT (@Medical/Nursing Services) experienced Đ° +0.11% price change this week, while ICUI (@Pharmaceuticals: Other) price change was -1.14% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.58%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -10.51%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.63%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +8.73%.
Reported Earning Dates
CLPT is expected to report earnings on Oct 28, 2026.
ICUI is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.58% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | -2.12% | ||
| ICUI - CLPT | 57% Loosely correlated | -0.15% | ||
| ISRG - CLPT | 46% Loosely correlated | -2.26% | ||
| A - CLPT | 45% Loosely correlated | +2.74% | ||
| NVST - CLPT | 45% Loosely correlated | +0.96% | ||
| SMTI - CLPT | 43% Loosely correlated | -1.12% | ||
More | ||||
ICUI and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICUI has been loosely correlated with CLPT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ICUI jumps, then CLPT could also see price increases.
| Ticker / NAME | Correlation To ICUI | 1D Price Change % | ||
|---|---|---|---|---|
| ICUI | 100% | -0.15% | ||
| CLPT - ICUI | 57% Loosely correlated | -2.12% | ||
| ALGN - ICUI | 50% Loosely correlated | +0.58% | ||
| A - ICUI | 50% Loosely correlated | +2.74% | ||
| MMSI - ICUI | 50% Loosely correlated | +0.24% | ||
| BLCO - ICUI | 49% Loosely correlated | +1.48% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SOXY | 85.85 | 1.74 | +2.07% |
| YieldMax Target 12 Semiconductor Option Income ETF (SOXY) | |||
| CORO | 35.90 | 0.18 | +0.50% |
| iShares International Country Rotation Active ETF (CORO) | |||
| EVNT | 12.27 | 0.02 | +0.16% |
| AltShares Event-Driven ETF (EVNT) | |||
| RNIN | 38.01 | -0.04 | -0.11% |
| Bushido Capital US SMID Cap Equity ETF (RNIN) | |||
| DIV | 18.98 | -0.04 | -0.21% |
| Global X SuperDividend US ETF (DIV) | |||